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Objectives. The aim of this study was to examine the left
ventricular mechanoenergetic effects of a novel Ca21 sensitizing
agent, MCI-154, on diseased human hearts compared with dobut-
amine.
Background. Unlike conventional cardiotonic agents, a Ca21
sensitizer that could produce a positive inotropic action by
altering the responsiveness of myofilament to Ca21 could generate
force with smaller amounts of Ca21; thus, it may potentially save
energy expenditure.
Methods. The left ventricular pressure-volume relation and
myocardial oxygen consumption per beat (VO2) were measured by
a conductance (volume) catheter and a Webster catheter. Left
ventricular contractility (Emax), systolic pressure-volume area
(PVA [index of left ventricular total mechanical energy]) and VO2
were assessed before and after infusion of MCI-154 or dobut-
amine. The PVA-independent VO2 (VO2 mainly for excitation-
contraction coupling) was assessed as the VO2 at zero PVA.
Results. Both agents increased Emax comparably (dobutamine:
from 3.55 6 1.10 [mean 6 SD] to 5.04 6 1.16 mm Hg/ml per m2,
p < 0.0001; MCI-154: from 3.36 6 1.26 to 5.37 6 2.14 mm Hg/ml
per m2, p < 0.0001); dobutamine increased total VO2 (from 0.226
0.08 to 0.27 6 0.09 ml O2, p < 0.05) and PVA-independent VO2
(from 0.019 6 0.019 to 0.091 6 0.051 ml O2, p < 0.005); but
MCI-154 did not change these variables significantly. Conse-
quently, the oxygen cost of contractility (DPVA-independent VO2/
DEmax) was less with MCI-154 than with dobutamine (0.14 6
0.18 vs. 1.10 6 0.80 J/mm Hg per ml per m2, p < 0.05).
Conclusions. These results suggest that the cardiotonic action
mediated by MCI-154 could provide an energetic advantage over
the conventional cardiotonic action with currently used inotropic
agents.
(J Am Coll Cardiol 1997;29:613–22)
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The two general mechanisms of cardiotonic agents are increas-
ing intracellular calcium concentration ([Ca21]i) and altering
the responsiveness of myofilament to Ca21 (1). The major
classes of cardiotonic agents in current use, including the
cardiac glycosides and catecholamine and phosphodiesterase
inhibitors, act through the former mechanism. However, when
[Ca21]i exceeds optimum, a further increase in [Ca
21]i would
be associated with the development of arrhythmia (2–4) and
an increase in myocardial oxygen consumption through the
increased myofibrillar ATPase activity and the greater energy
requirement for Ca21 cycling (5). Ca21 sensitizing agents
could generate additional force in the presence of a constant
Ca21 transient and may be able to increase the energy
efficiency of cross-bridge cycling, so that increasing force need
not necessarily require more energy consumption by either
Ca21 cycling or myofibrillar ATPase (5). Therefore, Ca21
sensitizing agents would have an energetic advantage over
conventional cardiotonic agents. As yet, however, there is little
evidence for their oxygen-saving property in the clinical setting
(6–9).
MCI-154 {6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-
3(2H)-pyridazinone hydrochloride trihydrate} is a newly de-
veloped cardiotonic agent accompanied by peripheral vasodi-
latory properties with a less prominent chronotropic effect
(10,11). This compound exerts a cardiotonic effect in vitro and
in vivo without the involvement of alpha- and beta-
adrenoreceptors and histamine and muscarinic acetylcholine
receptors (10,12). It was recently reported that MCI-154
increased the responsiveness of myofilament to Ca21 in an in
vitro motility assay (13) and in chemically skinned cardiac
muscle fibers from guinea pig (14) and human myocardium
(15). Furthermore, MCI-154 has been indicated to increase
ATPase activity of canine myofibril and reconstituted actomy-
osin for a given Ca21 concentration (16). Interestingly, MCI-
154 had 100 times more potent Ca21 sensitizing action than
sulmazole (13) and enhanced maximal Ca21 activated force in
addition to increasing the Ca21 concentration, producing 50%
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maximal activation of myofilament (14,15). In the present
study, we compared the mechanoenergetic effects of MCI-154
with those of dobutamine in diseased human hearts.
Methods
Patients. Seventeen patients with a previous myocardial
infarction without angina (mean age 61 years, range 52 to 69;
New York Heart Association functional classes I to III)
undergoing routine cardiac catheterization for evaluation of
heart disease were enrolled in the study. The study was
performed with patients in stable physical and cardiac condi-
tion 1 to 2 months after onset of myocardial infarction. Mean
left ventricular ejection fraction was 44%. Twenty-two patients
initially entered the study, but five did not complete the
protocol because of unsuccessful pressure-volume measure-
ments. Patients with valvular heart disease or high risk hemo-
dynamic instability were excluded. Written informed consent
was obtained before the study. The study protocol was ap-
proved by the institutional committee on human research at
Kobe University Hospital.
Catheterization procedure. All diuretic and vasodilator
medications were withheld for at least 24 h before the study.
Cardiac catheterization was performed with patients in the
fasting state through the femoral approach, as previously
described (17–22). After completion of routine catheterization,
an 8F conductance catheter (CardioDynamics; Rijnsberg, The
Netherlands) and a 2F microtip catheter pressure transducer
(Millar Instruments Inc.) were inserted into the left ventricle to
obtain instantaneous left ventricular pressure and volume data.
Heparinized saline solution was slowly and continuously in-
fused through the lumen of the conductance catheter to
prevent hemostasis. A 7F Swan-Ganz thermodilution catheter
(Goodtech Inc.) was advanced into the pulmonary artery for
measurement of cardiac output and injection of hypertonic
saline. A Webster catheter (Cordis Webster, Inc.) was ad-
vanced into the coronary sinus through the left subclavian 8F
sheath, as confirmed by contrast injection. Right atrial pacing
was by the tipped electrodes of the Webster catheter at 80 to
100 beats/min.
Measurement of left ventricular volume. The principle and
accuracy of left ventricular volume measurements using the
conductance catheter have been described in earlier reports
(23,24) and in our previous study (17). Briefly, instantaneous
left ventricular volume V(t) is computed as follows:
V~t! 5 1/az@L2zrzG~t! 2 aVc#, [1]
where G(t) is the instantaneous sum of the conductances; L is
the distance between two adjacent electrodes; r is a blood
resistivity in the left ventricle; 1/a is a gain constant, and aVc
is the correcting volume for the conductance of the surround-
ing tissues. Blood resistivity in the left ventricle was measured
in a calibrated cuvette; 1/a was determined individually by
obtaining the ratio of stroke volume determined by the ther-
modilution method to that measured by the conductance
catheter; aVc was estimated by bolus injection of 10 ml of
hypertonic saline (5% NaCl) into the pulmonary artery.
Measurement of myocardial oxygen consumption. Using
the Webster catheter advanced into the coronary sinus, coro-
nary sinus blood flow was measured at least twice during a 30-s
continuous injection of room temperature injector (5% glu-
cose) through the catheter lumen at a rate of 40 ml/min with
use of a Mark IV angiographic injector (Medrad Inc.). Coro-
nary venous blood was sampled from the distal lumen of the
Webster catheter for determination of myocardial oxygen
consumption. Myocardial oxygen consumption per minute was
calculated as the product of coronary sinus blood flow (ml/min)
and coronary arteriovenous oxygen content difference (vol%),
divided by heart rate to yield myocardial oxygen consumption
per beat, similar way to our previous studies (19,20).
Study protocol. Control study. After completion of calibra-
tion, atrial (coronary sinus) pacing was started at a fixed heart
rate (86 6 8 beats/min). Once steady state hemodynamic
variables, pressure-volume data and VO2 were measured,
inferior vena caval occlusions were performed several times
using a large balloon occlusion catheter (Baxter Healthcare,
Inc.). Then, to perform volume loading, 100 to 200 ml of 10%
dextran solution was carefully infused over 5 min two or three
times. After stabilization of hemodynamic variables was
achieved at each volume loading stage, steady state hemody-
namic variables pressure-volume data and VO2 were measured.
As previously described (19), PVA and VO2 were measured
twice at each volume loading stage; therefore, we obtained six
or eight points of VO2 and PVA in an individual heart. We
measured blood resistivity in the left ventricle and entered it
into the signal coordinator at each volume loading stage.
Inotropic agents study. After the control measurements, a
bolus injection of MCI-154 was administered carefully at a
dose of 1.5 mg/kg body weight, followed by a continuous
infusion of MCI-154 at 0.12 mg/kg per min in 10 patients. The
other seven patients received a continuous infusion of dobut-
amine at 6 mg/kg per min. This dosage of dobutamine pro-
duced an increase in Emax similar to that induced by MCI-154
(see Results). After a steadily enhanced contractile state was
achieved, we measured hemodynamic variables, pressure-
volume data and VO2. Furthermore, volume loading similar to
the control study was performed in 6 of 10 patients (Patients 12
Abbreviations and Acronyms
ANCOVA 5 analysis of covariance
[Ca21]i 5 intracellular calcium concentration
dP/dt 5 time derivative of left ventricular pressure
Ea 5 arterial elastance
Emax 5 left ventricular contractility
ESPVR 5 end-systolic pressure-volume relation
PVA 5 systolic pressure-volume area
VO2 5 myocardial oxygen consumption per beat
V0 5 volume axis intercept of end-systolic pressure-volume
relation
tau 5 time constant of left ventricular pressure decay
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to 17) at a stably enhanced contractile state to examine the
effects of MCI-154 on the slope of VO2–PVA relations.
Data analysis. End-systolic pressure-volume relation. The
left ventricular contractile state has been characterized by
means of the end-systolic pressure-volume relation (ESPVR)
(25,26). In the present study, ESPVR was calculated from
variably loaded pressure-volume loops during inferior vena
cava occlusion, as previously described (25,26). Thus,
ESP5 Emax~ESV2V0!, [2]
where ESP is the end-systolic pressure; ESV is the end-systolic
volume; Emax is the slope of ESPVR; and V0 is the volume
axis intercept of the ESPVR (Fig. 1).
Effective arterial elastance. Following the approach pro-
posed by Sunagawa et al. (27), we determined the effective
arterial elastance (Ea), a variable that incorporates the values
of Windkessel model elements and heart rate as the ratio of
end-systolic pressure to stroke volume. Thus,
Ea 5 ESP/SV, [3]
where ESP is the end-systolic pressure; SV is the stroke
volume; and Ea is the negative value of the slope of the
diagonal line connecting the end-systolic pressure-volume
point and the end-diastolic point on the volume axis (Fig. 1B).
External work and pressure-volume area. Left ventricular
external work was defined as the area of the pressure-volume
loop for each cardiac cycle. Following the approach of Sag-
wawa et al. (25) and Suga (26), pressure-volume area (PVA)
was defined as the area enclosed by the ESPVR line, the
end-diastolic pressure-volume relation curve and the systolic
trajectory of the pressure-volume loop. As shown in Figure 1B,
PVA is the sum of external work and potential energy stored in
the ventricle at end-systole, and represents the total mechan-
ical energy of the left ventricle generated by a contraction.
Mechanical efficiency. Left ventricular mechanical effi-
ciency was calculated as the ratio of external work (J/beat) to
VO2 (J/beat), similar to our previous study (19) and that of
others (28), where 1 mm Hg/ml of external work and 1 ml O2
of VO2 correspond to 0.000133 and 20 J, respectively.
VO2–PVA relation. According to experimental studies in
animal hearts (26,29–33) and our recent study in diseased
human hearts (18), the VO2 and PVA data during volume
loading were fit to a linear regression line. Thus,
VO2 5 aPVA1 b, [4]
where a is the slope of the regression line; b is the VO2
intercept; aPVA and b represent PVA-dependent and PVA-
independent VO2, respectively; PVA-independent VO2 (b)
reflects the VO2 for nonmechanical work (excitation–
contraction coupling and basal metabolism) (26).
Oxygen cost of contractility. Suga (26) and Ohgoshi et al.
(32) showed that the VO2 intercept of the VO2–PVA relation
(b) increases with an increase in Emax, but the slopes are
virtually the same, as schematically shown in Figure 2A. The
VO2 of a contraction at an enhanced Emax level consists of the
three components: PVA-dependent VO2, an increase in PVA-
independent VO2 and the same PVA-independent VO2 as the
control value. The sum of the second and the last VO2
components corresponds to the PVA-independent VO2 at the
enhanced contractile state. When the PVA-independent VO2
values of the VO2–PVA relations at different Emax levels were
plotted against Emax values, the relation was linear, as shown
schematically in Figure 2B (32). The relation was formulated
as
PVA2 independent VO2 5 cEmax1 d, [5]
where c represents the slope of this relation and d the
PVA-independent VO2 extrapolated to zero Emax. Suga (26)
and Ohgoshi et al. (32) showed that slope c represents the
“oxygen cost of contractility,” which indicates the increment in
VO2 per unit increment in contractility. We calculated the
PVA-independent VO2 at the enhanced contractile state on the
Figure 1. A, Representative pressure-volume
loops obtained by conductance catheter dur-
ing inferior vena cava occlusion. Emax and
V0 are the slope and volume axis intercept of
the end-systolic pressure-volume relation
(ESPVR), respectively. B, Representative
pressure-volume diagram showing method of
calculating systolic pressure-volume area
(PVA). PVA is the area enclosed by the
ESPVR line, the end-diastolic pressure-
volume curve and the systolic trajectory of
pressure-volume loop (hatched area). PVA
consists of potential energy (PE) and external
work (EW) and has been considered to rep-
resent the total mechanical energy generated
by contraction. Effective arterial elastance
(Ea) is the negative value of the slope of the
diagonal line connecting the end-systolic
pressure-volume point and end-diastolic point
on the volume axis and characterizes arterial
impedance.
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basis of parallelism of the VO2–PVA relation, which had been
confirmed in diseased human hearts during dobutamine infu-
sion in our previous study (18). The parallelism during MCI-
154 infusion was also validated directly in the present study, as
described later (see Results).
Statistics. Results are presented as mean value 6 SD,
unless otherwise indicated. The changes in variables were
compared by two-way repeated measures analysis of variance
between the two groups. The regression lines of the VO2–PVA
relations during control and MCI-154 infusions in individual
patients were also compared by analysis of covariance
(ANCOVA). A p value ,0.05 was considered statistically
significant.
Results
Table 1 shows the demographic and hemodynamic variables
in control contractile state. There was no difference in age,
infarct location, heart rate, end-systolic and end-diastolic pres-
sures or volumes or left ventricular ejection fraction between
the dobutamine and MCI-154 groups.
Effects of dobutamine and MCI-154 on hemodynamic vari-
ables. Table 2 summarizes the effects of dobutamine and
MCI-154 on hemodynamic variables. Both dobutamine and
MCI-154 decreased end-systolic volume (24 6 15% vs. 24 6
11%) and increased left ventricular ejection fraction (19 6
14% vs. 14 6 11%) and maximal positive value of time
derivative of left ventricular pressure (peak positive dP/dt)
(55 6 41% vs. 35 6 25%) to the same extent. Neither agent
changed heart rate, end-systolic pressure or systemic vascular
resistance. Dobutamine decreased peak negative dP/dt (2356
Figure 2. A, Schematic illustration of relation between left ventricular
oxygen consumption per beat (VO2) versus PVA. Based on the
parallelism of the VO2–PVA relation, VO2 of a contraction at an
enhanced Emax level consists of the three components: PVA-
dependent VO2, an increase in PVA-independent VO2 and the same
PVA-independent VO2 as a contraction at a control Emax level. B,
Schematic illustration of the relation between PVA-independent VO2
versus Emax. The increase in PVA-independent VO2 divided by the
increase in Emax was termed the oxygen cost of contractility. (Data
from Hata et al. [31].)
Table 1. Baseline Demographic and Angiographic Data
Pt
No.
Age (yr)/
Gender
Infarct
Location
CAG
[seg no. (% stenosis)]*
HR
(beats/min)
ESP
(mm Hg)
EDP
(mm Hg)
EDVI
(ml/m2)
ESVI
(ml/m2)
LVEF
(%)
Dobutamine Group
1 55/M Ant 7 (25%)† 90 148 3 87 45 48
2 57/M Ant 6 (100%) 80 167 19 158 106 33
3 64/M Inf 6 (50%)† 90 150 20 136 70 49
4 66/M Inf 2 (100%) 100 169 9 95 50 47
5 47/M Ant 9 (100%) 80 117 12 74 36 51
6 68/M Ant 7 (75%)† 90 109 23 54 32 41
7 60/M Ant 6 (50%)† 80 102 23 77 47 39
Mean 60 87 137 16 97 55 44
SD 7 88 28 8 37 26 7
MCI-154 Group
8 67/M Ant 7 (75%)† 80 111 12 98 54 45
9 70/M Inf 13 (100%) 80 138 27 93 48 48
10 59/M Ant 7 (25%)† 80 109 12 93 51 45
11 59/M Inf 13 (100%) 80 116 6 92 54 41
12 67/M Inf 2 (100%) 100 186 14 96 58 40
13 52/M Ant 6 (25%)† 90 145 25 100 55 45
14 61/M Ant 7 (25%)† 80 153 13 90 59 34
15 68/M Ant 13 (100%) 80 150 17 97 48 51
16 59/F Ant 6 (100%) 100 140 12 84 46 45
17 58/M Ant 7 (25%)† 80 111 8 118 74 37
Mean 62 85 136 15 96 55 43
SD 6 87 25 7 9 8 5
*American Heart Association classification. †Opened by percutaneous transluminal coronary angioplasty. Ant 5 anterior; CAG 5 coronary angiography; EDP 5
end-diastolic pressure; EDVI 5 end-diastolic volume index; ESP 5 end-systolic pressure; ESVI 5 end-systolic volume index; F 5 female; HR 5 heart rate; Inf 5
inferior; LVEF 5 left ventricular ejection fraction; M 5 male; Pt 5 patient; seg. 5 segment.
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23%) and tended to decrease the time constant of left ventric-
ular pressure decay (tau) (220 6 19%), whereas MCI-154 did
not change these variables. MCI-154 decreased pulmonary
capillary wedge pressure (242 6 16%), right atrial pressure
(239 6 21%) and end-diastolic pressure (233 6 15%) and
volume (214 6 7%), whereas dobutamine did not change
these variables.
Table 3 summarizes the effects of dobutamine and MCI-154
on mechanoenergetic variables. Both dobutamine and MCI-
154 increased Emax to the same extent (47 6 35% vs. 60 6
30%) without altering V0 and Ea. Dobutamine increased
external work (28 6 19%), PVA (13 6 27%) and VO2 (26 6
19%), resulting in an increase in external work/PVA ratio
(22 6 18%) and an unchanged external work/VO2 ratio.
MCI-154 did not change external work and VO2 but decreased
PVA (217 6 19%), resulting in an increase in the external
work/PVA ratio (28 6 24%) and an unchanged external
work/VO2 ratio.
Comparison of hemodynamic variables between baseline and
after volume loading during MCI-154 infusion (Fig. 3). Because
MCI-154 exhibited a marked preload reduction, hemodynamic
variables after volume loading with dextran infusion during
MCI-154 infusion (6 of 10 patients) were compared with
baseline values to eliminate the influence of the altered loading
condition with MCI-154 on myocardial oxygen consumption.
When preload was augmented moderately to achieve an
end-diastolic pressure comparable to that at baseline (MCI-
154 1 Dex1), there was no difference in PVA or VO2 between
baseline and MCI-154 1 Dex1. Furthermore, when preload
was markedly augmented to achieve a higher end-diastolic pres-
sure than that at baseline (MCI-154 1 Dex2), there was still no
difference in VO2 between baseline and MCI-1541Dex2 despite
an increase in PVA. These results may imply that the mechanical
unloading (decreases in PVA) may not play a central role in
saving myocardial oxygen consumption with MCI-154.
Variables of VO2–PVA relations during control conditions.
Table 4 summarizes the variables of the VO2–PVA relations
during control conditions assessed directly using volume load-
ing. In all patients, VO2 linearly correlated with PVA, and the
correlation coefficients of the VO2–PVA relations were close to
unity. There was no difference in the mean values of the slope
or the VO2 intercept between the two groups.
Table 2. Effects of Dobutamine and MCI-154 on Hemodynamic Variables
Dobutamine (n 5 7) MCI-154 (n 5 10) Drug Interaction
(two-way
ANOVA)Pre Post Pre Post
HR (beats/min) 87 6 8 87 6 8 85 6 6 87 6 9 NS
PCWP (mm Hg) 16 6 7 15 6 8 13 6 4 5 6 3* , 0.0001
RAP (mm Hg) 6 6 3 6 6 1 7 6 3 4 6 3* , 0.05
ESP (mm Hg) 128 6 26 144 6 28 135 6 11 132 6 16 , 0.05
EDP (mm Hg) 17 6 10 16 6 8 21 6 4 14 6 3† , 0.01
EDVI (ml/m2) 103 6 35 93 6 39 104 6 17 89 6 11 NS
ESVI (ml/m2) 59 6 25 46 6 26† 56 6 14 42 6 10* NS
LVEF (%) 43 6 6 52 6 9† 47 6 6 53 6 7* NS
SVR (dyneszszcm25) 2,564 6 774 2,372 6 813 2,560 6 375 2,578 6 450 NS
dP/dt max (mm Hg/s) 1,473 6 258 2,280 6 665* 1,876 6 343 2,499 6 392* NS
dP/dt min (mm Hg/s) 21,452 6 243 21,922 6 224* 22,068 6 456 22,518 6 956 , 0.01
tau (ms) 56 6 8 44 6 10 48 6 9 47 6 6 , 0.05
*p , 0.01, †p , 0.05 versus before drug administration value (Pre). ANOVA 5 analysis of variance; dP/dt max 5 maximal positive value of time derivative of left
ventricular pressure; dP/dt min5minimal positive value of time derivative of left ventricular pressure; PCWP5 pulmonary capillary wedge pressure; Post5 after drug
administration; RAP 5 right atrial pressure; SVR 5 systemic vascular resistance; tau 5 time constant of left ventricular pressure decay; other abbreviations as in Table 1.
Table 3. Effects of Dobutamine and MCI-154 on Mechanoenergetic Variables
Dobutamine (n 5 7) MCI-154 (n 5 10) Drug Interaction
(two-way
ANOVA)Pre Post Pre Post
Emax (mm Hg/ml per m2) 3.55 6 1.10 5.04 6 1.16* 3.36 6 1.26 5.37 6 2.14† NS
Ea (mm Hg/ml per m
2) 3.15 6 1.12 3.33 6 0.99 3.18 6 0.82 3.27 6 0.98 NS
V0 (ml/m
2) 21 6 30 17 6 28 10 6 16 13 6 15 NS
EW (mm Hg/ml) 6,314 6 1,274 8,201 6 2,311* 6,721 6 1,298 7,116 6 1,629 NS
PVA (mm Hg/ml) 12,519 6 3,383 14,322 6 5,504 13,426 6 2,480 11,027 6 2,849* , 0.05
EW/PVA 0.52 6 0.08 0.62 6 0.08* 0.51 6 0.07 0.64 6 0.09† NS
VO2 (ml O2/min) 0.22 6 0.08 0.29 6 0.09* 0.22 6 0.06 0.20 6 0.06 , 0.01
EW/VO2 0.21 6 0.08 0.22 6 0.09 0.21 6 0.03 0.25 6 0.06 NS
*p, 0.05, †p, 0.01 versus before drug administration value (Pre). Ea 5 effective arterial elastance; Emax5 slope of end-systolic pressure-volume relation; EW5
external work; PVA 5 systolic pressure-volume area; V0 5 volume intercept of end-systolic pressure-volume relation; VO2 5 myocardial oxygen consumption per beat;
other abbreviations as in Table 2.
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Effects of MCI-154 on VO2–PVA relations. Table 5 and
Figure 4 show the effects of MCI-154 on the VO2–PVA
relation. In 6 of 10 patients, we directly assessed the VO2–PVA
relation during MCI-154 infusion using volume loading and
found that VO2 also linearly correlated with PVA after MCI-
154 infusion. ANCOVA showed that MCI-154 did not affect
the slope (all six patients) or the VO2 intercept (three of six
patients) of the VO2–PVA relation. On the contrary, direct
assessment of the VO2–PVA relation during dobutamine infu-
sion consistently exhibited a significant increase in the VO2
intercept in our previous study (19).
Effects of dobutamine and MCI-154 on oxygen cost of con-
tractility. Table 6 shows the effects of dobutamine and MCI-
154 on Emax and PVA-independent VO2. Dobutamine in-
creased the PVA-independent VO2 (from 0.0188 6 0.0191 to
0.08616 0.0574 ml O2, p, 0.05), but MCI-154 did not change
significantly when both agents increased Emax to a similar
degree (Fig. 5A). Consequently, the oxygen cost of contractility
was less with MCI-154 than with dobutamine (0.14 6 0.18 vs.
1.10 6 0.80 J/mm Hg per ml per m2, p , 0.05) (Fig. 5B).
Discussion
In the present study, we examined the effects of a novel
Ca21 sensitizing agent, MCI-154, on left ventricular mecha-
noenergetics versus those of dobutamine. The major findings of
this study are: 1) Total myocardial oxygen consumption in-
creased with dobutamine but not with MCI-154 in diseased
human hearts; 2) MCI-154 did not change the VO2 intercept of
the VO2–PVA relation, in contrast to the results of our
previous study (18), where dobutamine consistently increased
the VO2 intercept; and 3) the oxygen cost of contractility was
significantly smaller with MCI-154 than dobutamine.
Mechanical unloading by MCI-154 and myocardial ener-
getics. When both dobutamine and MCI-154 increased left
ventricular contractility (Emax) comparably, MCI-154 de-
creased end-diastolic and pulmonary artery wedge pressures,
whereas dobutamine did not. Unlike phosphodiesterase inhib-
itors, MCI-154 did not change Ea or systemic vascular resis-
tance (19). MCI-154 acted predominantly on veins rather than
arteries. A marked preload reduction induced by MCI-154 may
have been attributed to the modest increases in cardiac output
and external work compared with those during dobutamine.
Myocardial oxygen consumption did not change with MCI-
154, whereas it increased with dobutamine. Reducing left
ventricular preload with MCI-154 decreased PVA, which may
have possibly contributed to the lack of increase in myocardial
oxygen consumption. In our previous study comparing the
mechanoenergetic effects of a phosphodiesterase inhibitor with
those of dobutamine in diseased human hearts, reducing the
arterial afterload with a phosphodiesterase inhibitor improved
ventriculoarterial coupling, decreased PVA and hence saved
myocardial oxygen consumption (19). Thus, to eliminate the
influence of the altered loading condition with MCI-154 on
myocardial oxygen consumption, we compared hemodynamic
variables after volume loading during MCI-154 infusion with
Figure 3. Bar graphs showing left ventricular end-diastolic pressure
(EDP) (A), external work (EW) (B), systolic pressure-volume area
(PVA) (C) and myocardial oxygen consumption per beat (VO2) (D) at
baseline and during MCI-154 infusion at lower preload (MCI-154), at
preload comparable to baseline (MCI-154 1 Dex1) and at augmented
preload (MCI-154 1 Dex2) in 6 of 10 patients. #p , 0.05. Dex 5
dextran solution.
Table 4. Variables of VO2 Relation During Control Conditions
Pt No.
Slope of
VO2–PVA Relation
(1025zml O2/mm Hg per ml)
VO2 Intercept of
VO2–PVA
Relation (ml O2/min)
r
Value
Dobutamine Group
1 0.33 0.0532 0.95
2 2.24 0.0038 0.96
3 1.79 0.0290 0.88
4 1.48 0.0089 0.99
5 2.09 0.0110 0.99
6 2.38 0.0277 0.71
7 1.17 20.0021 0.87
Mean 1.64 0.0188 0.91
SD 0.72 0.0191 0.09
MCI-154 Group
8 2.92 20.0902 0.97
9 2.01 0.0252 0.96
10 0.97 0.0428 0.98
11 1.70 0.0541 0.99
12 1.13 0.0510 0.81
13 0.99 0.0587 0.81
14 1.46 0.0083 0.99
15 2.70 20.1170 0.88
16 1.52 20.0012 0.98
17 0.94 0.0875 0.95
Mean 1.63 0.0119 0.93
SD 0.71 0.0663 0.07
r5 correlation coefficient of regression line; other abbreviations as in Tables
1 and 3.
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baseline values. Theoretically, for a given PVA, VO2 should be
higher than at baseline during positive inotropic stimulation
due to an increase in PVA-independent VO2. When preload
was markedly augmented to achieve a higher end-diastolic
pressure than that at baseline, PVA increased to a level similar
to baseline, but VO2 still did not differ from that at baseline.
Therefore, mechanical unloading may not play a central role
for saving myocardial oxygen consumption with MCI-154.
Ca21 sensitization by MCI-154 and myocardial energetics.
In the concept of the VO2–PVA relation, an increase in total
myocardial oxygen consumption with cardiotonic agents is
divided into increases in PVA-dependent VO2 (VO2 for me-
chanical work) and PVA-independent VO2 (VO2 for nonme-
chanical work, mainly for Ca21 handling) (26). Another pos-
sible mechanism for saving myocardial oxygen consumption
would be reducing PVA-independent VO2. Experimental stud-
ies (26,29–33) have indicated that PVA-independent VO2
reflects the VO2 for excitation–contraction coupling and basal
metabolism. Ca21 sensitizing agents could generate additional
force in the presence of a constant Ca21 transient, so increas-
ing force need not necessarily require more energy consump-
tion by Ca21 cycling (4). Therefore, we hypothesized that Ca21
sensitizing agents would lessen the increase in the PVA-
independent VO2 and spare the oxygen cost of contractility
compared with that of dobutamine. In the present study,
dobutamine increased total myocardial oxygen consumption
and PVA-independent VO2 (Table 6, Fig. 4A). In contrast to
dobutamine, MCI-154 did not increase the total myocardial
oxygen consumption or PVA-independent VO2 significantly
(Table 6, Fig. 4A). Furthermore, the oxygen cost of contrac-
tility was significantly smaller with MCI-154 than dobutamine.
These results are consistent with our hypothesis.
Inconsistent with our hypothesis, indicated earlier, previous
studies (31,34) failed to show that other Ca21 sensitizers,
pimobendan and EMD 53998, spared the oxygen cost of
contractility in isolated normal canine heart. Because a metab-
olite of pimobendan and a negative isomer of EMD 53998 are
potent phosphodiesterase inhibitors (8,35,36), an increase in
intracellular cyclic adenosine monophosphate with these com-
pounds will lead to a decrease in Ca21 sensitivity through the
phosphorylation of troponin I (37). Thus, the Ca21 sensitizing
actions of these agents may have been attenuated by an
increase in cyclic adenosine monophosphate. Another possible
explanation of the inconsistency may be that Ca21 sensitizers
were studied in normal hearts in those studies. Our previous
study (38) suggested that the oxygen cost of contractility in
human dysfunctioning left ventricle is higher than in the
normal left ventricle. Suspected higher baseline oxygen cost of
contractility in our patients with left ventricular dysfunction
may be responsible for the energetic advantage of MCI-154
over dobutamine.
Is PVA-independent VO2 small and negligible relative to
total myocardial oxygen consumption? In the present study,
the fractions of VO2 for external work, VO2 for potential energy
and PVA independent VO2/total VO2 ratio during control
Figure 4. Plots showing VO2–PVA relations in the control (open
circles and dotted lines) and enhanced contractile states (solid circles
and solid lines) with MCI-154 infusion in the individual patients. VO2
was linearly correlated with PVA before and after infusion of MCI-154
in all patients. In these patients, the slope of VO2–PVA relation was
not affected by MCI-154 (by ANCOVA).
Table 5. Effects of MCI-154 on VO2–PVA Relations
Pt No.
Slope
(1025 ml O2/
mm Hg
per ml)
VO2
intercept
(ml O2)
r
Value
Slope
(ANCOVA)
Intercept
(ANCOVA)
12
Control 1.33 0.0510 0.805*
MCI-154 1.24 0.0541 0.854* NS NS
13
Control 0.99 0.0587 0.808*
MCI-154 1.23 0.0314 0.914* NS NS
14
Control 1.46 0.0083 0.987*
MCI-154 1.21 0.0379 0.947* NS NS
15
Control 2.70 20.1170 0.882*
MCI-154 2.40 20.0559 0.976* NS †
16
Control 1.52 20.0012 0.906*
MCI-154 1.30 0.0559 0.929* NS ‡
17
Control 0.94 0.0875 0.947*
MCI-154 1.53 0.0446 0.821* NS †
Control
Mean 1.46 0.0146
SD 0.65 0.0724
MCI-154
Mean 1.49 0.0280
SD 0.46 0.0421
p value NS NS
*Significant correlation. †p , 0.05, ‡p , 0.005 by analysis of covariance
(ANCOVA). Control 5 control contractile state; MCI-154 5 enhanced contrac-
tile state by MCI-154; other abbreviations as in Tables 1, 3 and 4.
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conditions were 40 6 11%, 40 6 8% and 20 6 15%, respec-
tively (Fig. 6B). The amount of PVA-independent VO2 does
not appear to be negligible. Moreover, PVA-independent VO2
increased significantly with dobutamine (Table 6, Fig. 6A) so
that the fraction of PVA-independent VO2 during dobutamine
infusion rose to 35 6 18% (Fig. 6B). In contrast, PVA-
independent VO2 tended to increase (p 5 0.15) (Table 6, Fig.
6A) with MCI-154, and the fraction of PVA-independent VO2
during MCI-154 infusion did not change significantly to 28 6
15% (p 5 NS) (Fig. 6B).
Ca21 sensitization and diastolic function. Ca21 sensitizing
agents, which shift the force–Ca21 relation to the left, enhance
the force at low [Ca21]i (i.e., during diastole). Thereby, Ca
21
sensitizing agents would compromise left ventricular relaxation
and filling dynamics. Moreover, it has been demonstrated (39)
that the diastolic [Ca21]i during end-stage heart failure was
significantly higher than that in the nonfailing heart. In our
present and previous studies (22), peak negative dP/dt and
time constant of left ventricular pressure decay actually de-
creased with MCI-154 but to a significantly smaller extent than
with dobutamine, which may be attributed in part to the Ca21
sensitizing action of MCI-154. The lusitropic actions of Ca21
sensitizing agents are still problematic, especially in the setting
of severe heart failure.
Study limitations. There are several potential sources of
error in the calculation of the VO2–PVA relation in the present
study:
1. Left ventricular wall motion abnormalities may affect the
pressure-volume measurements by the conductance catheter
method. In our previous study (17), we compared the left
ventricular volume-time curve measured by the conductance
method with that of biplane cineventriculography in human
Figure 5. A, Plots showing relation between PVA-independent VO2
versus Emax before and after enhancement of the contractile state
with dobutamine infusion (open circles) and MCI-154 infusion (solid
circles). Slopes of the solid and dashed lines indicate DPVA-
independent VO2/DEmax. Note that the slope was steeper with dobut-
amine (dashed line) than with MCI-154 (solid line). B, Bar graphs
showing the oxygen cost of contractility with cardiotonic agents. *p ,
0.05, dobutamine versus MCI-154.
Table 6. Effects of Dobutamine and MCI-154 on Emax and PVA-Independent VO2
Pt
No.
Emax
(mm Hg/ml per m2)
PVA-Independent VO2
(ml O2/min)
Oxygen Cost of
Contractility
(J/mm Hg per ml per m2)Pre Post Pre Post
Dobutamine Group
1 2.49 4.01 0.0532 0.1630 1.44
2 3.19 4.36 0.0038 0.1123 1.85
3 3.79 4.93 0.0290 0.1504 2.13
4 5.77 6.86 0.0089 0.0404 0.58
5 3.85 5.24 0.0110 0.0145 0.59
6 2.81 6.18 0.0278 0.0781 0.30
7 2.97 3.67 20.0021 0.0440 1.32
Mean 3.55 5.04* 0.0188 0.0861* 1.17
SD 1.10 1.16 0.0191 0.0574 0.70
MCI-154 Group
8 5.46 6.07 20.0902 20.0824 0.26
9 4.27 7.89 0.0252 0.0456 0.11
10 2.09 2.69 0.0428 0.0400 20.09
11 2.64 3.93 0.0541 0.0701 0.25
12 3.92 7.91 0.0510 0.0537 0.01
13 3.70 7.38 0.0587 0.0274 20.17
14 4.79 6.99 0.0083 0.0165 0.07
15 2.23 3.55 20.1170 20.0926 0.37
16 2.73 4.84 20.0012 0.0241 0.24
17 1.72 2.50 0.0875 0.1003 0.33
Mean 3.36 5.37† 0.0119 0.0203‡ 0.14‡
SD 1.26 2.14 0.0663 0.0618 0.18
*p , 0.05, †p , 0.01 versus before drug administration (Pre). ‡p , 0.05 versus dobutamine. Other abbreviations as
in Tables 1 and 3.
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left ventricle with and without regional wall motion abnormal-
ities and found no difference in the slopes, intercepts, corre-
lation coefficients or standard error of estimates.
2. Right ventricular VO2 may affect the results because our
measurements of VO2 might contain right ventricular VO2
whereas our measurements of PVA did not contain right
ventricular PVA. However, it is well recognized, that right
ventricular wall stress and dP/dt are low compared with that for
the left ventricle. Right ventricular PVA would also be low
compared with that for left ventricular PVA. Although we did
not assess right ventricular VO2 exclusively in the present study,
we could thus speculate that the influence of right ventricular
VO2 on total VO2 may be minimal.
3. The assumption of the linear end-systolic pressure-
volume relation must be considered. Previous studies (40)
suggested that the contractility-dependent curvilinearity of the
end-systolic pressure-volume relation may exist. Both MCI-154
and dobutamine increased Emax to a similar degree. The
influence of the contractility-dependent curvilinearity of the
end-systolic pressure-volume relation may not explain the
large difference in the oxygen cost of contractility between
MCI-154 and dobutamine.
4. Mechanical unloading of right heart provided by venodi-
lating action with MCI-154 may have influenced the measure-
ment of coronary sinus flow with the Webster catheter.
The present study included a relatively small number of
patients with mild to moderate left ventricular dysfunction.
These results may not be directly applied to the other Ca21
sensitizers or other subgroups of patients. Moreover, these
results provide only short-term effects so that they should not
be extended to the potential effects on prognosis. Further
studies will be needed to elucidate whether Ca21 sensitizers
have energetic and prognostic advantage over conventional
inotropic agents in patients with severe left ventricular dys-
function.
Conclusions. We studied the mechanoenergetic effects of a
novel Ca21 sensitizing agent, MCI-154, on diseased human
hearts compared with those of dobutamine. Our results dem-
onstrated that MCI-154 was superior to dobutamine with
regard to increasing mechanical efficiency and sparing the
oxygen cost of contractility when both agents increased left
ventricular contractility to a similar degree. These findings
suggest that the cardiotonic action mediated by MCI-154 could
provide an energetic advantage over the conventional car-
diotonic action with currently used cardiotonic agents.
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